Seminars in Nephrology
Volume 24, Issue 2 , Pages 168-175 , March 2004

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues

  • Amy J Mangrum

      Affiliations

    • Department of Medicine, Division of Nephrology, University of Virginia, Charlottesville, VA, USA
    • ,
  • George L Bakris

      Affiliations

    • Department of Preventive Medicine, Rush Hypertension/Clinical Research Center, Chicago, IL, USA
    • Corresponding Author InformationAddress reprint requests to George Bakris, MD, Rush Medical College, 1700 W. Van Buren St., Suite 470, Chicago, IL 60612 USA

References 

  1. Chobanian AV, Bakris GL, Black HR, et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 Report). JAMA. 2003;289:2560–2571
  2. Wright JT, Bakris G, Greene T, et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease (Results from the AASK trial). JAMA. 2002;288:2421–2431
  3. Ruggenenti P, Perna A, Mosconi L, et al.  Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int Suppl. 1997;63:S54–S57
  4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD  The Collaborative Study Group . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1461
  5. Lewis EJ, Hunsicker LG, Clarke WR, et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  6. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease (The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease). N Engl J Med. 1982;307:652–659
  7. Kostis JB, Shelton B, Gosselin G, et al.  Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J. 1996;131:350–355
  8. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol. 1977;233:F366–F372
  9. Schnermann J, Briggs JP, Weber PC. Tabuloglomerular feedback, prostaglandins, and angiotensin in the autoregulation of glomerular filtration rate. Kidney Int. 1984;25:53–64
  10. Navar LG. Renal autoregulation (Perspectives from whole kidney and single nephron studies). Am J Physiol. 1978;234:F357–F370
  11. Johnson PC. Autoregulation of blood flow. Circ Res. 1986;59:483–495
  12. Harder DR, Gilbert R, Lombard JH. Vascular muscle cell depolarization and activation in renal arteries on elevation of transmural pressure. Am J Physiol. 1987;253:F778–F781
  13. Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med. 1979;301:9–12
  14. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev. 1979;59:137–164
  15. Johnson HA, Vera Roman JM. Compensatory renal enlargement. Hypertrophy versus hyperplasia. Am J Pathol. 1966;49:1–13
  16. Anderson S, Meyer TW, Brenner BM. The role of hemodynamic factors in the initiation and progression of renal disease. J Urol. 1985;133:363–368
  17. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925–1930
  18. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612–619
  19. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000
  20. Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens. 1996;5:89–96
  21. Maschio G, Alberti D, Janin G, et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–945
  22. Maschio G, Alberti D, Janin G, et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945
  23. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863
  24. Klahr S, Levey AS, Beck GJ, et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–884
  25. Reams GP, Bauer JH. Effect of lisinopril monotherapy on renal hemodynamics. Am J Kidney Dis. 1988;11:499–507
  26. Brown SA, Brown CA. Single-nephron adaptations to partial renal ablation in cats. Am J Physiol. 1995;269:R1002–R1008
  27. Yoshioka T, Shiraga H, Yoshida Y, et al.  Intact nephrons as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest. 1988;82:1614–1623
  28. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992;41:891–897
  29. Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol. 1998;9:2096–2101
  30. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans (Importance of therapeutic selection). Kidney Int. 1992;41:912–919
  31. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest. 1995;96:793–800
  32. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:1849–1860
  33. Brenner BM, Cooper ME, de Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  34. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1996;30:55–61
  35. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?. Arch Intern Med. 1998;158:26–32
  36. Abraham PA, Opsahl JA, Halstenson CE, Keane WF. Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. Arch Intern Med. 1988;148:2358–2362
  37. Carlsen JE, Hansen FM, Jensen HA. Efficacy and safety of cilazapril in hypertensive patients with moderate to severe renal impairment. Am J Med. 1989;87:79S–82S
  38. Kifor I, Moore TJ, Fallo F, et al.  Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology. 1991;129:823–831
  39. Rabinowitz L. Aldosterone and potassium homeostasis. Kidney Int. 1996;49:1738–1742
  40. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine (Is this a cause for concern?). Arch Intern Med. 2000;160:685–693
  41. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med. 1982;73:719–725
  42. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98–101
  43. Keilani T, Danesh F, Schlueter W, Molleni A, Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis. 1999;33:450–457
  44. Bakris GL, Siomos M, Richardson D, et al.  VAL-K Study Group   ACE inhibition or angiotensin receptor blockade (Impact on potassium in renal failure). Kidney Int. 2000;58:2084–2092
  45. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl. 1994;12:S37–S42
  46. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) (A randomised controlled trial). Lancet. 2003;361:117–124
  47. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–242
  48. Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE. Resolution of ACF inhibitor cough (Changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P). Br J Clin Pharmacol. 1995;40:423–429
  49. Lacourciere Y, Brunner H, Irwin R, et al.  Losartan Cough Study Group   Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 1994;12:1387–1393
  50. Lacourciere Y  Telmisartan Cough Study Group . The incidence of cough (a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist). Int J Clin Pract. 1999;53:99–103
  51. Pavletic AJ. Late angio-oedema in patients taking angiotensin-converting-enzyme inhibitors. Lancet. 2002;360:493–494
  52. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 1997;278:232–233
  53. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med. 1995;333:1572
  54. Pitts DB. Nondiabetic kidney disease. N Engl J Med. 2003;348:762–763
  55. Rose BD, Post TW. In: Clinical Physiology of Acid-Base and Electrolyte Disorders. 5th ed.. New York: McGraw-Hill; 2001;p. 383–396

PII: S0270-9295(03)00191-8

doi: 10.1016/j.semnephrol.2003.11.001

Seminars in Nephrology
Volume 24, Issue 2 , Pages 168-175 , March 2004

Article Tools